SCHEMBL14153105

SCHEMBL14153105

N#Cc1ccc(-c2cccc(F)c2)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRG2 P18507 2/20 0.48
GABRB3 P28472 2/20 0.48
GABRA5 P31644 2/20 0.48
GABRA3 P34903 2/20 0.48
TAAR1 Q96RJ0 2/20 0.46
ESR2 Q92731 1/20 0.46
EGLN2 Q96KS0 1/20 0.46
MAP4K4 O95819 2/20 0.45
CTSA P10619 1/20 0.44
CHEK1 O14757 1/20 0.44
ADORA2A P29274 1/20 0.43
ADORA2B P29275 1/20 0.43
ADORA1 P30542 1/20 0.43
CYP11B2 P19099 5/20 0.43
KDM4E B2RXH2 1/20 0.42
HPGD P15428 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
DGAT1 O75907 1/20 0.42
CYP11B1 P15538 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17117049 0.87 EGLN2 (0.49) EGLN2MAP4K4CTSACHEK1CYP11B2
SCHEMBL12496522 0.82 CHEK1 (0.49) EGLN2CHEK1CYP11B2KDM4EHPGD
SCHEMBL13681290 0.81 TNF (0.49) EGLN2MAP4K4CTSACHEK1ADORA2A
SCHEMBL18461760 0.81 EGLN2 (0.44) EGLN2MAP4K4CTSACHEK1ADORA2A
SCHEMBL6241092 0.81 CTSS (0.58) CYP11B2KDM4EDGAT1CYP11B1
SCHEMBL70602 0.80 CHEK1 (0.63) GABRG2GABRB3GABRA5GABRA3EGLN2
SCHEMBL31588411 0.80 CHEK1 (0.63) GABRG2GABRB3GABRA5GABRA3EGLN2
SCHEMBL12630708 0.79 CHEK1 (0.51) EGLN2CTSACHEK1CYP11B2DGAT1
SCHEMBL18462125 0.79 CHEK1 (0.44) GABRG2GABRB3GABRA5GABRA3EGLN2
SCHEMBL16675750 0.78 CHEK1 (0.60) EGLN2CTSACHEK1CYP11B2CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012162635-A1 METABOTROPIC GLUTAMATE RECEPTORS 5 MODULATORS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-11-29 WO disclosed